首页 › 转移性癌症 › 佛罗里达州 › Plantation
Plantation FL 转移性癌症临床试验
6项针对 转移性癌症的研究正在 Plantation及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Plantation
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
招募中1/2 期
- Florida Clinical Trials Group, Plantation
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
招募中1 期
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- University of Miami-SCCC-Plantation, Plantation
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
招募中3 期
- BRCR Medical Center, Inc- Internal Medicine, Plantation
其他城市的 转移性癌症试验
- Houston, TX104 项研究
- New York City, NY93 项研究
- Nashville, TN70 项研究
- Boston, MA63 项研究
- Los Angeles, CA57 项研究
- St. Louis, MO54 项研究
- Arlington, VA53 项研究
- Philadelphia, PA46 项研究
- Chicago, IL45 项研究
- San Antonio, TX44 项研究
- Washington, DC43 项研究
- Dallas, TX42 项研究
Plantation的其他研究
- 非小细胞肺癌16 项研究
- 乳腺癌14 项研究
- 癌症(所有类型)7 项研究
- 狼疮7 项研究
- 肺癌7 项研究
- 类风湿关节炎6 项研究
- 前列腺癌5 项研究
- 银屑病关节炎5 项研究
- 结直肠癌5 项研究
- 黑色素瘤4 项研究
- 多发性骨髓瘤4 项研究
- 小细胞肺癌4 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。